Jumat, 13 Maret 2026

Friday's Radar Pings Low Float (Nasdaq: IVF) And 5 Key Potential Catalysts (Strong Analyst Target)

Any content you receive is for information purposes only. Always conduct your own research.

*Sponsored

Friday's Radar Pings Low Float (Nasdaq: IVF) And 5 Key Potential Catalysts (Strong Analyst Target)


*Click Here To Get Our Alerts Faster Via SMS*


March 13th

Greetings Readers,


The fertility landscape is undergoing a striking transformation.


With the global market projected to surge from $42.37Bn in 2026 to nearly $92.60Bn by 2035—an impressive 8.96% annual growth rate—one innovative organization is rethinking how people and clinics approach assisted reproduction.


Its breakthrough model challenges conventions, lowers systemic barriers, and expands access to care in ways that were once thought unattainable.


As demand accelerates and new technology reshapes possibilities, this group’s approach stands out as a bold force driving change across an industry that touches millions of lives.


And with a very low float below 2Mn shares, a recently closed acquisition, and strong news throughout the early part of 2026, this under-the-radar Nasdaq profile tops Friday's watchlist:


INVO Fertility, Inc. (Nasdaq: IVF)


INVO Fertility is a heal-thcare services fertility company dedicated to expanding access to assisted reproductive technology (“ART”) care to patients in need.


Their principal commercial strategy is focused on building, acquiring, and operating fertility clinics, including “INVO Centers” dedicated primarily to offering the intravaginal culture (“IVC”) procedure enabled by their INVOcell® medical device (“INVOcell”) and US-based, pro-fit-able in vitro fertilization (“IVF”) clinics.


And based on multiple potential catalysts, (Nasdaq: IVF) has taken over the top spot on our Friday watchlist. Check them out:


#1. A Very Low Float Could Surround IVF With Potential Volatility In Seconds.


#2. A Maxim Group Analyst Has Tagged IVF With A $4 Target.


#3. A Closed Acquisition Acts As An Important Milestone In This Company's Growth Journey.


#4. The Company's Wisconsin Clinic Receives A Boost From The Adoption Of Time-Lapse Incubation Technology.


#5. Another Major Company Milestone Was Achieved Through IP Patent Protection Through 2040.


But more on those in a second...

Key Company Highlights - Results, Operating Focus & Market Trends


Revenue Growth


  • Driven by fertility services, including M&A strategy


Momentum Building Toward Breakeven


  • Adjusted EBITDA loss reduced from approximately -$8.4Mn in 2022 to -$2.2Mn in 2024


Attractive acquisition pipeline


  • In preliminary discussions to acquire additional US-based, profitable fertility clinics and/or related businesses


  • Working to close one new acquisition in 2025 to narrow gap to cash flow breakeven (targeted for 2026)


Positive Macro Trends


  • Demand supported by lower birth and higher infertility rates


  • U.S. President executive order to further support IVF expansion

-----


Company Evolution - Expanding Focus In The Fertility Market

Growth Strategy - Become A Leading Provider Of Fertility Services And Technology

About INVOcell


INVOcell offers a gentle, innovative approach to fertility.


It’s the first FDA-cleared medical device designed to help make the journey to parenthood more natural and connected.


Through intravaginal culture (IVC), INVOcell allows fertilization and early embryo development to take place inside a body, providing a unique, more intimate alternative to traditional fertility treatments.


How It Works

Critical Takeaways

Grab Sources And More: IVF Website. IVF Presentation.

-----


And as I mentioned above, (Nasdaq: IVF) has hit our radar behind 5 potential catalysts. Check them out:


#1. IVF Potential Catalyst - A Very Low Float Could Surround IVF With Potential Volatility In Seconds.


According to info from the Yahoo Finance websiteIVF has a very low float.


In fact, the website reports this profile to have approximately 1.73Mn shares in its float.


Why is that important? It's important on one crucial level. Volatility potential.


If the company provides positive news towards the first part of 2026, could it help provide a breakout spark when paired with this volatility potential?

-----


#2. IVF Potential Catalyst - A Maxim Group Analyst Has Tagged IVF With A $4 Target.


The Maxim Group has built one of the premier proprietary research platforms on Wall Street, with an emphasis on small-cap, micro-cap, and emerging growth companies.


Jason McCarthy, a senior analyst at Maxim Group covering the biotechnology sector, has suggested an $4.00 target for INVO Fertility, Inc. (IVF) as of 3/5/26 according to published info on the company’s website.


With this $4.00 target, there could be upside potential of over 350% for IVF from its closing valuation Thursday.

-----


#3. IVF Potential Catalyst - A Closed Acquisition Acts As An Important Milestone In This Company's Growth Journey.


INVO Fertility Closes Acquisition of Indiana-Based Fertility Clinic “Family Beginnings”


Strategic Transaction Advances Company’s Growth


SARASOTA, Fla., Feb. 19, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), ..., today announced that it has successfully closed the previously announced acquisition of Family Beginnings, P.C., a respected fertility clinic serving patients across Indiana and the broader Midwest.


...


Family Beginnings generated revenue of approximately $1Mn and net income of approximately $0.2Mn for the 9 months ended September 30, 2025, or approximately 18% of INVO’s clinic revenue for the same period.


The closing of this acquisition marks an important milestone in INVO’s ongoing strategy to expand its network of fertility care centers and broaden patient access to advanced reproductive care. ...


We are thrilled to complete the acquisition of Family Beginnings,said Steve Shum, CEO of INVO Fertility.This transaction not only expands our geographic footprint and enhances our portfolio of clinics, but it also advances our mission of increasing access to high-quality, patient-centered fertility care. Family Beginnings has a long-standing reputation for excellence and compassionate care, and we look forward to building on that legacy with Dr. Donahue and growing the clinic from its current operating levels.


...


Read the full article here.

-----


#4. IVF Potential Catalyst - The Company's Wisconsin Clinic Receives A Boost From The Adoption Of Time-Lapse Incubation Technology.


INVO Fertility Announces Availability of Advanced Incubation Technology at its Wisconsin Clinic


Time-Lapse Incubation Provides Additional Cutting-Edge Solution for Patient Care


SARASOTA, Fla., March 05, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), ..., today announced the adoption of time-lapse incubation technology at its Wisconsin clinic. This integration reflects INVO’s commitment to providing high-quality, modern laboratory care and innovative patient solutions, and to in-vest-ing in laboratory excellence and clinical quality across its growing network of clinics.


INVO Fertility is proud to introduce this technology as part of our ongoing focus on quality and innovation and the expansion of additional patient service offerings,said April McGhee, COO of INVO.This technology enhances the tools available to our embryology teams while aligning with our commitment to delivering thoughtful, patient-centered fertility care.


...


Our approach to innovation is intentional,added Steve Shum, CEO.We focus on technologies that may enhance quality and outcomes while staying true to our mission of expanding access to fertility care through continuous, responsible innovation.


...


Read the full article here.

-----


#5. IVF Potential Catalyst - Another Major Company Milestone Was Achieved Through IP Patent Protection Through 2040.


INVO Fertility Announces Patent Issuance for Modified INVOcell® Device


New patent extends intellectual property protection on the Company’s INVOcell device through 2040


SARASOTA, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), ..., today announced the final issuance of a U.S. patent covering a modified version of its proprietary INVOcell® device. The patent (U.S. Patent No. 12,544,204 B2) became effective on February 10, 2026, providing intellectual property protection on the INVOcell device through 2040.


...


We are pleased to see our previously announced patent allowance conclude with this official issuance, which marks an important milestone for INVO Fertility as we continue to strengthen the intellectual property foundation around the INVOcell platform,said Steve Shum, CEO of INVO Fertility.INVOcell provides an additional treatment method in the fertility market, enabling fertilization and early embryo development to occur within the patient’s body rather than a traditional laboratory incubator. This expanded IP coverage supports our growth strategy and our mission to deliver high-quality fertility care through ongoing innovation.


Read the full article here.

-----


(Nasdaq: IVF) Recap - 5 Potential Catalysts Hit Our Radar


#1. A Very Low Float Could Surround IVF With Potential Volatility In Seconds.


#2. A Maxim Group Analyst Has Tagged IVF With A $4 Target.


#3. A Closed Acquisition Acts As An Important Milestone In This Company's Growth Journey.


#4. The Company's Wisconsin Clinic Receives A Boost From The Adoption Of Time-Lapse Incubation Technology.


#5. Another Major Company Milestone Was Achieved Through IP Patent Protection Through 2040.

-----


We're officially kicking-off coverage on INVO Fertility, Inc. (Nasdaq: IVF).


Be on the lookout for updates coming soon. Talk shortly.


Sincerely,

Kai Parker

StockWireNews


(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)


*StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.


Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 03/12/2026 and ending on 03/13/2026 to publicly disseminate information about (IVF:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC seventeen thousand five hundred USD ("Funds"). These Funds were part of the twenty four thousand USD funds that TD Media LLC received from a third party named Organized Noise LLC who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.


Neither SWN Media LLC, TD Media LLC and their member own shares of (IVF:US).


Please see important disclosure information here: https://stockwirenews.com/disclosure/ivf-ch7fl/#details

Tidak ada komentar:

Posting Komentar